Qing Ma, Ph.D.
Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX
Professor (Joint appointment), Stem Cell Transplantation - Research, University of Texas MD Anderson Cancer Center, Houston, TX
Member, Immunology Program, University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Stem Cell Transplantation - Research, University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1995 | Thomas Jefferson University, Philadelphia, Pennsylvania, US, Genetics, Ph.D |
| 1988 | Fudan University, Shanghai, CN, Biochemistry, BS |
Postgraduate Training
| 2001-2002 | Research Fellowship, Transplantation, Fred Hutchinson Cancer Research Center, Seattle, Washington |
| 1995-2001 | Research Fellowship, Immunology, Harvard Medical School, Boston, Massachusetts |
Experience & Service
Faculty Academic Appointments
Associate Professor, Stem Cell Transplantation - Research, University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2019
Assistant Professor, Stem Cell Transplantation - Research, University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2010
Research Associate, Transplantation Biology Section, Fred Hutchinson Cancer Research Center, Seattle, WA, 2001 - 2002
Post-doctoral Fellow, Department of Pathology, Harvard Medical School, Boston, MA, 1995 - 2001
Other Professional Positions
Member, GSBS Student Scholarship Committee, Houston, Tx, 2024 - Present
Strategic Advisor, Tranquil Clinical and Research Consulting Services, Houston TX, 2020 - 2021
Scientific Advisery Board, CLS Therapeutics, New York, NY, 2019 - 2022
Member, GSBS Academic Standards Committee, Houston, TX, 2018 - 2021
Member, MDACC Trainee Research Day Poster Award Committee, Houston, TX, 2014
Consultantships, Guardum Pharmaceuticals, Boston, MA, 2014
Advisory Board, Alexion Pharmaceuticals, Cheshire, CT, 2013
Member, GSBS McGovern Award Committee, Houston, 2012
Member, Faculty Recognition and Award Committee, Houston, TX, 2011
Member, GSBS Curriculum Committee, Houston, TX, 2009 - 2011
Member, GSBS Knudson Outstanding Dissertation Award Committee, Houston, TX, 2009
Member, Center for Inflammation and Cancer, University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Chair, GSBS Student Affairs Committee, Houston, TX, 2008 - 2009
Member, GSBS Executive Committee, Houston, TX, 2008 - 2009
Member, GSBS Gigli Family Scholarship Review Committee, Houston, TX, 2008
Member, GSBS Floy Haar, M.D. Endowed Memorial Research Award Committee, Houston, TX, 2008
Member, GSBS Student Affairs Committee, Houston, TX, 2006 - 2009
Member, GSBS Sowell-Huggins Scholarship Committee, Houston, TX, 2004
Member, Center for Cancer Immunology Research, Houston, TX, 2003 - Present
Member, Immunology Program, University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), Houston, TX, 2003 - Present
Member, GSBS Research Day Poster Award Committee, Houston, TX, 2003
Research Technician, Fudan University, Shanghai, 1988 - 1990
Extramural Institutional Committee Activities
CRTEC liaison, CCSG Immunology program, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, HBM Chair Search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021
Member, Start-up Funds Review, The University of Texas MD Anderson Cancer Center, 2020
Member, Research Faculty Appointment (RFA) Progress Review, The University of Texas MD Anderson Cancer Center, 2019
Member, Study Section Review Committee for the Institutional Research Grants (IRG), The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Graduate Education Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2018
Member, CCTS-MRP Grant Review Committee, The University of Texas MD Anderson Cancer Center, 2012
Member, Designated Member Review Committee (IACUC), The University of Texas MD Anderson Cancer Center, 2010 - 2011
Member, Institutional Animal Care and Use Committee (IACUC), The University of Texas MD Anderson Cancer Center, 2007 - 2011
Editorial Activities
Editor, Journal of Regenerative Therapeutics, 2015 - Present
Editor, Frontiers in Immunology, 2015 - Present
Editor, World Journal of Biological Chemistry, 2010 - Present
Editor, International Journal of Immunology Research, 2010 - Present
Editor, Journal of Stem Cell Research & Therapy, 2009 - Present
Honors & Awards
| 2008 - 2012 | American Cancer Society Research Scholar, American Cancer Society |
| 1995 - 1998 | Irvington Fellowship Award, Irvington Institute for Immunological Research |
Selected Presentations & Talks
National Presentations
- 2019. Complement system regulates graft-versus-host disease (GVHD). Conference. Complement system regulates graft-versus-host disease (GVHD). Key Biscayne, FL, US.
- 2016. Post-transplant bendamustine vs. cyclophosphamide for prevention of GVHD. Conference. Post-transplant bendamustine vs. cyclophosphamide for prevention of GVHD. San Diego, CA, US.
International Presentations
- 2017. LFA-1 activation in leukemia immunotherapy. Conference. LFA-1 activation in leukemia immunotherapy. Prague, CZ.
- 2015. Complement system in GVHD. Conference. Complement system in GVHD. Crete, GR.
- 2012. LFA‐1 affinity regulation in cancer immunotherapy. Conference. LFA‐1 affinity regulation in cancer immunotherapy. Montreal, CA.
- 2011. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Conference. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Philadelphia, US.
- 2010. LFA-1 activation modulates CTL function. Conference. LFA-1 activation modulates CTL function. Loutraki, GR.
- 2009. Regulation of LFA-1 activation with mAb and statin in autoimmunity and timor immunity. Conference. Regulation of LFA-1 activation with mAb and statin in autoimmunity and timor immunity. Shanghai, CN.
- 2009. LFA-1 Regulates Erk1/2 Signal Pathways in CD8 T Cells. Conference. LFA-1 Regulates Erk1/2 Signal Pathways in CD8 T Cells. Hona, US.
Formal Peers
- 2016. T cell activation in Graft versus Host Disease. Invited. Houston, TX, US.
- 2016. Vimentin regulates T cell migration and activation in GVHD. Invited. Houston, TX, US.
- 2015. LFA-1 affinity regulation in immunity. Invited. Bethlehem, PA, US.
- 2013. Immunological Synapse and T Cell Activation. Invited. Bethesda, MD, US.
- 2009. Regulation of LFA-1 Activation with mAB and Statin in Autoimmunity and Tumor Immunity. Invited. La Jolla, CA, US.
- 2009. LFA-1 Activation in Alloimmunity and Tumor Immunity. Invited. Bethesda, MD, US.
- 2008. Adhesion Molecules and Immune Responses. Invited. Shanghai, CN.
- 2004. Chemokine Receptors in Hematopoiesis and Immune Responses. Invited. Houston, TX, US.
- 2003. Chemokine Receptors in Alloimmunity. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | Exploring the interplay between B cells and platelets in regulating pro-tumor immunity within the ovarian tumor microenvironment |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| ID: | BU00030098 |
| Date: | 2024 - 2026 |
| Title: | Effect of SIRP alpha mismatch on the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) ) from an HLA matched related donor R03 CA232444-01 |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2024 - 2029 |
| Title: | Platelets promote growth of ovarian cancer |
| Funding Source: | Other |
| Role: | Co-I |
| ID: | R01 HL139560-01 |
| Date: | 2022 - 2023 |
| Title: | SIRPα mismatch and the outcome of Allo-HSCT in patients with hematologic malignancy |
| Funding Source: | UTMDACC IRG-Clinical/Translational Research |
| Role: | Collaborator |
| Date: | 2022 - 2022 |
| Title: | Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis |
| Funding Source: | UTMDACC IRG-Clinical/Translational Research |
| Role: | Collaborator |
| Date: | 2021 - 2022 |
| Title: | COVID-19: A Study to Collect Peripheral Blood, Tissue and Bone Marrow Samples from Donors and Receipients of Blood and Marrow Transplants for Laboratory Research |
| Funding Source: | Tranquil Clinical and Research |
| Role: | PI |
| Date: | 2018 - 2024 |
| Title: | Genetics of graft versus host disease |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA231141-01 |
| Date: | 2018 - 2019 |
| Title: | The interaction between the complement system and VWF after bone marrow transplant |
| Funding Source: | American Society of Hematology Bridge Fund |
| Role: | Collaborator |
| Date: | 2017 - 2020 |
| Title: | T follicular helper (Tfh) cells in the pathogenesis of CLL |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | TRP-13242-17 |
| Date: | 2017 - 2018 |
| Title: | Preclinical study to evaluate to Filgotinib (JAK1 inhibitor) in a murine model of acute GVHD |
| Funding Source: | Gilead |
| Role: | PI |
| ID: | RCTS53506 |
| Date: | 2017 - 2022 |
| Title: | Targeting Vimentin in alloimmune responses and GVHD |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 1 R01 AI132664-01 (53 percentile) |
| Date: | 2016 - 2019 |
| Title: | A novel approach to treat GVHD |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP170464 IIRA |
| Date: | 2016 - 2019 |
| Title: | Ibrutinib regulates Tfh Development in Acute GVHD |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP170464 IIRA |
| Date: | 2016 - 2018 |
| Title: | Role of NLRC5/Class I transactivator in the pathogenesis of GVHD |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP160878 HIHR |
| Date: | 2016 - 2021 |
| Title: | Targeting pathogenic properties of Tfh cells in acute and chronic GVHD |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 1 R01 AI123446-01 |
| Date: | 2015 - 2017 |
| Title: | Pilot Tolerability, Viability and Biodistribution Study of a Cellular Therapy Product in NOD/SCID Mice |
| Funding Source: | Celltex Therapeutics |
| Role: | PI |
| Date: | 2015 - 2020 |
| Title: | The Role of Complement System in Graft versus Host Disease |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 CA194554-01 |
| Date: | 2014 - 2017 |
| Title: | Investigation of ex vivo fucosylation to enhance the efficacy of adoptive T cell immunotherapy |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| ID: | P-TRP-1997-14 |
| Date: | 2014 - 2017 |
| Title: | Panzem suppresses alloreactivity in acute GVHD |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | TRP-2349-14 |
| Date: | 2014 - 2019 |
| Title: | Cell Therapy Subproject: 8F4-CAR T cells for patients with AML |
| Funding Source: | MDS/AML Moon Shot |
| Role: | Co-I |
| Date: | 2014 - 2017 |
| Title: | Complement system modulates immune responses in GVHD |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP140574 IIRA |
| Date: | 2014 - 2019 |
| Title: | LFA-1 and CD8+ T cell function in immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 CA184455-01 |
| Date: | 2013 - 2017 |
| Title: | Complement system in GVHD |
| Funding Source: | Alexion Pharmaceuticals |
| Role: | PI |
| ID: | 00001515 |
| Date: | 2013 - 2018 |
| Title: | The Complement System in Graft versus Host Disease |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 1 R01 AI107037-01(50 percentile) |
| Date: | 2013 - 2023 |
| Title: | UT M.D. Anderson Cancer Center SPORE-Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2P50CA100632-16 |
| Date: | 2012 - 2015 |
| Title: | LFA-1 affinity regulation in cancer immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP130226 IIRA |
| Date: | 2012 - 2014 |
| Title: | The Role of Complement System in Graft-versus-Host-Disease |
| Funding Source: | UTMDACC IRG-Clinical/Translational Research |
| Role: | PI |
| Date: | 2012 - 2015 |
| Title: | The role of complement system in alloimmune responses |
| Funding Source: | NIH/NIAID |
| Role: | PI |
| ID: | 1R21AI101932-01 |
| Date: | 2012 - 2017 |
| Title: | LFA-1 affinity regulation in GVHD and leukemia immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01 CA164580-01A1 (34 percentile) |
| Date: | 2012 - 2015 |
| Title: | DNase I in mouse GVHD |
| Funding Source: | CLS Therapeutics, Inc |
| Role: | PI |
| ID: | 2012-00036611RG |
| Date: | 2011 - 2015 |
| Title: | An Anti-PR1/HLA-A2 Antibody as Novel Therapy for Myeloid Malignancies |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-PI |
| ID: | TRP6030-12 |
| Date: | 2011 - 2024 |
| Title: | Improving cord blood transplantation |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 5P01CA148600-01A1 |
| Date: | 2010 - 2011 |
| Title: | Mechanism of Posttransplant Thrombotic Microangiopathy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP101362 |
| Date: | 2008 - 2013 |
| Title: | LFA-1 Affininty Regulation and T Cell Mediated Alloimmunity |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| ID: | RSG-08-183-01-LIB |
| Date: | 2008 - 2008 |
| Title: | Improving Antigen-Specific T Cell Therapy by Modulating LFA-1 Aciviation |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | PI |
| Date: | 2006 - 2007 |
| Title: | The role of chemokine receptors in immunotherapy |
| Funding Source: | Wendy Will Case Cancer Fund |
| Role: | PI |
| Date: | 2004 - 2005 |
| Title: | Cellular immunotherapy of cancer |
| Funding Source: | Institutional Multi-disciplinary Research Program |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Li D, Cho MS, Gonzalez-Delgado R, Liang X, Dong JF, Cruz MA, Ma Q, Afshar-Kharghan V. The effect of ADAMTS13 on graft-versus-host disease, 2024. e-Pub 2024. PMID: 38963011.
- Maen A, Gok Yavuz B, Mohamed YI, Esmail A, Lu J, Mohamed A, Azmi AS, Kaseb M, Kasseb O, Li D, Gocio M, Kocak M, Selim A, Ma Q, Kaseb AO. Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Front Pharmacol 15:1291212, 2024. e-Pub 2024. PMID: 38379905.
- Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, Rondon G, Ciurea SO, Ma Q, Shpall EJ, Champlin RE, Cao K. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer 129(8):1205-1216, 2023. e-Pub 2023. PMID: 36738229.
- Cho MS, Lee H, Gonzalez-Delgado R, Li D, Sasano T, Carlos-Alcalde W, Ma Q, Liu J, Sood AK, Afshar-Kharghan V. Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626102.
- Bencheqroun H, Ahmed Y, Kocak M, Villa E, Barrera C, Mohiuddin M, Fortunet R, Iyoha E, Bates D, Okpalor C, Agbosasa O, Mohammed K, Pondell S, Mohamed A, Mohamed YI, Gok Yavuz B, Kaseb MO, Kasseb OO, Gocio MY, Tu PT, Li D, Lu J, Selim A, Ma Q, Kaseb AO. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2. Pathogens 11(5), 2022. e-Pub 2022. PMID: 35631072.
- Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia 36(5):1324-1335, 2022. e-Pub 2022. PMID: 35149845.
- Zou J, Kongtim P, Oran B, Kosmoliaptsis V, Carmazzi Y, Ma J, Li L, Rondon G, Srour S, Copley HC, Partlow D, Ciurea SO, Greenbaum U, Ma Q, Shpall EJ, Champlin RE, Cao K. Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica 107(4):844-856, 2022. e-Pub 2022. PMID: 34435482.
- Zou J, Kongtim P, Srour SA, Greenbaum U, Schetelig J, Heidenreich F, Baldauf H, Moore B, Saengboon S, Carmazzi Y, Rondon G, Ma Q, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO, Cao K. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol 13:1033871, 2022. e-Pub 2022. PMID: 36311784.
- Saliba RM, Srour SA, Greenbaum U, Ma Q, Carmazzi Y, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Li D, Saengboon S, Alousi AM, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol 13:904718, 2022. e-Pub 2022. PMID: 35874659.
- Saliba RM, Greenbaum U, Ma Q, Srour SA, Carmazzi Y, Li L, Oran B, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Partlow D, Li D, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou J. Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv 5(17):3407-3417, 2021. e-Pub 2021. PMID: 34495313.
- Lu S, Tallis E, Ding X, Li D, Cox K, You MJ, St John L, Alatrash G, Ma Q, Molldrem JJ. Novel myeloperoxidase-derived HLA-A2 restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy 23(9):793-798, 2021. e-Pub 2021. PMID: 34215503.
- He H, Kondo Y, Ishiyama K, Alatrash G, Lu S, Cox K, Qiao N, Clise-Dwyer K, St John L, Sukhumalchandra P, Ma Q, Molldrem JJ. Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia 34(6):1626-1636, 2020. e-Pub 2020. PMID: 31908357.
- Ma Q, Li D, Vasquez HG, You MJ, Afshar-Kharghan V. Kidney Injury in Murine Models of Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 25(10):1920-1924, 2019. e-Pub 2019. PMID: 31271886.
- Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe S, Overwijk WW, Molldrem JJ, Ma Q, Shpall EJ, Mittendorf EA. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res 25(8):2610-2620, 2019. e-Pub 2019. PMID: 30647079.
- Yang TH, St John LS, Garber HR, Kerros C, Ruisaard KE, Clise-Dwyer K, Alatrash G, Ma Q, Molldrem JJ. Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201(5):1389-1399, 2018. e-Pub 2018. PMID: 30021768.
- Trujillo-Ocampo A, Cho HW, Herrmann AC, Ruiz-Vazquez W, Thornton AB, He H, Li D, Qazilbash MA, Ma Q, Porcelli SA, Shpall EJ, Molldrem J, Im JS. Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20(8):1089-1101, 2018. e-Pub 2018. PMID: 30076070.
- Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ. Targeting the Leukemia Antigen PR1 with Immunotherapy for the treatment of Multiple Myeloma. Clin Cancer Res 24(14):3386-3396, 2018. e-Pub 2018. PMID: 29661776.
- Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res 77(19):5374-5383, 2017. e-Pub 2017. PMID: 28819024.
- Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SLC, Kunapuli S, Ma Q, Sood AK, Afshar-Kharghan V. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood 130(10):1235-1242, 2017. e-Pub 2017. PMID: 28679740.
- Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ. Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. J Biol Chem 292(24):10295-10305, 2017. e-Pub 2017. PMID: 28468826.
- Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 31(1):234-237, 2017. e-Pub 2017. PMID: 27573556.
- Ma Q, Zhou D, DeLyria ES, Wen X, Lu W, Thapa P, Liu C, Li D, Bassett RL, Overwijk WW, Hwu P, Li C. Synthetic poly(L-glutamic acid)-conjugated CpG exhibits antitumor efficacy with increased retention in tumor and draining lymph nodes after intratumoral injection in a mouse model of melanoma. J Immunother 40(1):11-20, 2017. e-Pub 2017. PMID: 27681378.
- Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31(3):697-704. e-Pub 2016. PMID: 27654852.
- St John LS, Wan L, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ, Bollard CM, Ma Q, Molldrem JJ. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy 18(8):995-1001, 2016. e-Pub 2016. PMID: 27378343.
- Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy 18(8):985-94, 2016. e-Pub 2016. PMID: 27265873.
- Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You MJ, Gagea M, Ma Q, Molldrem JJ. Activity of 8F4, a T cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. Leukemia 30(7):1475-84, 2016. e-Pub 2016. PMID: 27055866.
- Li D, Patenia R, Bassett R, Zweidler-McKay P, Alousi AM, Champlin RE, Molldrem JJ, Mak TW, Ma Q. 2-Methoxyestradiol Treatment Prevents Graft-versus-Host Disease While Preserving Graft-versus-Leukemia Effect in Mice. Biol Blood Marrow Transplant 22(3):S405-406, 2016. e-Pub 2016.
- Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K. Complement-binding Donor-specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1392-8, 2015. e-Pub 2015. PMID: 25985919.
- Li D, Patenia BS, Bassett R, Tetz G, Champlin RE, Ma Q. DNase I Treatment Reduces GVHD in Mice. Biol Blood Marrow Transplant 21(2):S339, 2015. e-Pub 2015.
- Ma Q, Li D, Carreño R, Patenia R, Tsai KY, Xydes-Smith M, Alousi AM, Champlin RE, Sale GE, Afshar-Kharghan V. Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD. Bone Marrow Transplant 49(7):972-6, 2014. e-Pub 2014. PMID: 24777193.
- Puebla-Osorio N, Kim J, Ojeda S, Zhang H, Tavana O, Li S, Wang Y, Ma Q, Schluns KS, Zhu C. A novel Ku70 function in colorectal homeostasis separate from nonhomologous end joining. Oncogene 33(21):2748-57, 2014. e-Pub 2014. PMID: 23752193.
- Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. J Immunol 189(11):5476-84, 2012. e-Pub 2012. PMID: 23105141.
- Ma Q, Li D, Nurieva R, Patenia R, Bassett R, Cao W, Alekseev AM, He H, Molldrem JJ, Kroll MH, Champlin RE, Sale GE, Afshar-Kharghan V. Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol Blood Marrow Transplant 18(8):1174-81, 2012. e-Pub 2012. PMID: 22664751.
- Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L, Clise-Dwyer K, Molldrem JJ. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 117(16):4262-72, 2011. e-Pub 2011. PMID: 21296998.
- Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 2010. e-Pub 2010. PMID: 20735170.
- Li D, Li Y, Hernandez JA, Patenia R, Kim TK, Khalili J, Dougherty MC, Hanley PJ, Bollard CM, Komanduri KV, Hwu P, Champlin RE, Radvanyi LG, Molldrem JJ, Ma Q. Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. J Immunother 33(9):975-82, 2010. e-Pub 2010. PMID: 20948439.
- Carreño R, Brown WS, Li D, Hernandez JA, Wang Y, Kim TK, Craft JW, Komanduri KV, Radvanyi LG, Hwu P, Molldrem JJ, Legge GB, McIntyre BW, Ma Q. 2E8 binds to the high affinity I-domain in a metal ion-dependent manner: a second generation monoclonal antibody selectively targeting activated LFA-1. J Biol Chem 285(43):32860-8, 2010. e-Pub 2010. PMID: 20724473.
- Palmer LA, Sale GE, Balogun JI, Li D, Jones D, Molldrem JJ, Storb RF, Ma Q. Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. Biol Blood Marrow Transplant 16(3):311-9, 2010. e-Pub 2010. PMID: 20025985.
- Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma Q. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant 15(12):1513-22, 2009. e-Pub 2009. PMID: 19896074.
- Kim TK, St John LS, Wieder ED, Khalili J, Ma Q, Komanduri KV. Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production. J Immunol 183(10):6167-74, 2009. e-Pub 2009. PMID: 19841187.
- Li D, Molldrem JJ, Ma Q. LFA-1 Regulates CD8+ T Cell Activation via T Cell Receptor-mediated and LFA-1-mediated Erk1/2 Signal Pathways. J Biol Chem 284(31):21001-10, 2009. e-Pub 2009. PMID: 19483086.
- Ma Q, Gooley TA, Storb RF. CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease. Biol Blood Marrow Transplant 16:132-133, 2009. e-Pub 2009. PMID: 20053336.
- Wang Y, Li D, Nurieva R, Yang J, Sen M, Carreño R, Lu S, McIntyre BW, Molldrem JJ, Legge GB, Ma Q. LFA-1 affinity regulation is necessary for the activation and proliferation of naïve T cells. J Biol Chem 284(19):12645-53, 2009. e-Pub 2009. PMID: 19297325.
- Freedman RS, Ma Q, Wang E, Gallardo ST, Gordon IO, Shin JW, Jin P, Stroncek D, Marincola FM. Migration deficit in monocyte-macrophages in human ovarian cancer. Cancer Immunol Immunother 57(5):635-45, 2008. e-Pub 2008. PMID: 17926037.
- Carreño R, Li D, Sen M, Nira I, Yamakawa T, Ma Q, Legge GB. A mechanism for antibody-mediated outside-in activation of LFA-1. J Biol Chem 283(16):10642-48, 2008. e-Pub 2008. PMID: 18199751.
- Toba Y, Tiong JD, Ma Q, Wray S. CXCR4/SDF-1 system modulates development of GnRH-1 neurons and the olfactory system. Dev Neurobiol 68(4):487-503, 2008. e-Pub 2008. PMID: 18188864.
- Kaul M, Ma Q, Medders KE, Desai MK, Lipton SA. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. Cell Death Differ 14(2):296-305, 2007. e-Pub 2007. PMID: 16841089.
- Wang X, Deavers M, Patenia R, Bassett RL, Jr, Mueller P, Ma Q, Wang E, Freedman RS. Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease. J Transl Med 4:30, 2006. e-Pub 2006. PMID: 16824216.
- Ma Q, Shimaoka M, Lu C, Jing H, Carman CV, Springer TA. Activation-induced conformational changes in the I domain region of lymphocyte function-associated antigen 1. J Biol Chem 277(12):10638-41, 2002. e-Pub 2002. PMID: 11792712.
- Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B-lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10(4):463-71, 1999. e-Pub 1999. PMID: 10229189.
- Parolin C, Borsetti A, Choe H, Farzan M, Kolchinsky P, Heesen M, Ma Q, Gerald C, Palu G, Dorf ME, Springer T, Sodroski J. Use of Murine CXCR-4 as a second receptor by some T-cell-tropic human imunnodeficiency virus. J Virol 72(2):1652-6, 1998. e-Pub 1998. PMID: 9445072.
- Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, Bronson RT, Springer TA. Impaired B-lymphopoiesis, myelopiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 95(16):9448-53, 1998. e-Pub 1998. PMID: 9689100.
- Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ, Buchberg AM, Jimenez SA. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6(4):300-13, 1996. e-Pub 1996. PMID: 8723723.
- Ma Q, Alder H, Nelson KK, Chatterjee D, Gu Y, Nakamura T, Canaani E, Croce, C, M, Siracusa LD, Buchberg AM. Analysis of the murine ALLl-1gene reveals conserved domains with human ALL-1 and identifies a motif shared with DNA methyltransferases. Proc Natl Acad Sci USA 9(13):6350-4, 1993. e-Pub 1993. PMID: 8327517.
Review Articles
- Sizova O, John LS, Ma Q, Molldrem JJ. Multi-faceted role of LRP1 in the immune system. Front Immunol 14:1166189, 2023. e-Pub 2023. PMID: 37020553.
- Kaseb AO, Mohamed YI, Malek AE, Raad II, Altameemi L, Li D, Kaseb OA, Kaseb SA, Selim A, Ma Q. The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. Pathogens 10(3), 2021. e-Pub 2021. PMID: 33809851.
- Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant 24(5):895-908, 2018. e-Pub 2018. PMID: 29339270.
- Lu S, Wieder E, Komanduri K, Ma Q, Molldrem JJ. Vaccines in Leukemia. Adv Pharmacol 51:255-70, 2004. e-Pub 2004. PMID: 15464913.
Other Articles
- He H, Vedia RA, Lu S, Li Q, Cox KR, St John L, Sergeeva A, Clise-Dwyer K, Alatrash G, Shpall EJ, Ma Q, Molldrem JJ Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo, 2024. PMID: 39033444.
Patient Reviews
CV information above last modified July 22, 2026